Chimeric Antigen Receptor Therapy

Summary

This interview with Dr. Carl June discusses chimeric antigen receptor (CAR) therapy, focusing on T-cell engineering for durable remissions in refractory tumors and highlighting toxicities like cytokine release syndrome and neurologic dysfunction.

Key findings

• CAR therapy aims for durable remissions in treatment-refractory tumors.
• Toxic effects include cytokine release syndrome.
• Toxic effects include neurologic dysfunction.

Methods

• T-cell engineering
• Synthetic immunity

Limitations

• Toxic effects of CAR therapies.
• Cytokine release syndrome.
• Neurologic dysfunction.

Applications

• Treatment of treatment-refractory tumors.